Delving into the Latest Updates on RevM10/polAS transduced hematopoietic stem cells(Systemix) with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms-

Target-

Mechanism

Gene transference

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Non-Hodgkin Lymphoma

Originator Organization

Systemix, Inc.

Active Organization-

Inactive Organization

Systemix, Inc.

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
PURPOSE: Phase I/II trial to study the effectiveness of RevM10-treated stem cells plus chemotherapy and peripheral stem cell transplantation in treating patients who have HIV-related non-Hodgkin's lymphoma.

Start Date01 Nov 1998

Sponsor / Collaborator

Systemix, Inc.

[+1]

100 Clinical Results associated with RevM10/polAS transduced hematopoietic stem cells(Systemix)

Login to view more data

100 Translational Medicine associated with RevM10/polAS transduced hematopoietic stem cells(Systemix)

Login to view more data

100 Patents (Medical) associated with RevM10/polAS transduced hematopoietic stem cells(Systemix)

Login to view more data

100 Deals associated with RevM10/polAS transduced hematopoietic stem cells(Systemix)

Login to view more data